Table 3.
Infections after the treatments in two groups
|
Group R (N = 49) |
Group C (N = 40) |
P value | |
|---|---|---|---|
| Infected patients | 17 | 13 | .976 |
| Infected cases | 30 | 28 | – |
| Death cases | 1 | 1 | 1.000 |
| Etiology | |||
| Bacterial | 17 | 11 | .186 |
| Tuberculosis | 3 | 0 | |
| Fungal | 4 | 7 | .257 |
| Viral | 0 | 2 | – |
| Concurrent | 9 | 8 | .905 |
| Infected sites | |||
| Respiratory | 22 | 20 | .871 |
| Upper | 0 | 1 | |
| Lung | 22 | 19 | |
| Other sites | 8 | 8 | – |
| Skin and soft tissue | 2 | 4 | .608 |
| Gastrointestinal | 2 | 0 | – |
| Central nervous system | 1 | 2 | 1.000 |
| Urinary tract | 0 | 0 | – |
| Bacteremia | 3 | 2 | 1.000 |
Abbreviations: Group C, patients with treatments of cyclophosphamide; Group R, patients with treatments of low‐dose rituximab.